April 1, 2014
Otsuka Pharmaceutical and Eisai announced on March 31 that the two companies have entered into an agreement under which Otsuka will receive rights from Eisai’s US-based subsidiary Eisai Inc. to the DNA methylation inhibitor Dacogen (decitabine) as well as patent...read more